thyroid disease in pregnancy
in review
4 min read
Updated 2026-11-19
thyroid disease in pregnancy
Overt hyperthyroidism (Graves): PTU in T1 (up to 16 weeks; ratio 20 mg PTU : 1 mg methimazole) → methimazole from T2 at the lowest dose keeping free T4 at/slightly above the upper third of normal; never give RAI or isotope scans. Distinguish Graves from self-limited gestational transient thyrotoxicosis (GTT) (no ATDs). Pre-existing hypothyroidism: increase levothyroxine ~25–30% (2 extra tablets/week) at positive pregnancy test and revert to pre-pregnancy dose after delivery.
pregnancy thyroid physiology and screening
- Physiology: rising oestrogen increases TBG (total T4/T3 rise ~1.5× by 16 weeks); rising hCG cross-reacts with the TSH receptor, suppressing first-trimester TSH (→ physiology and lab interpretation in pregnancy). Use trimester-specific reference ranges; free T4 assays can drift downward in late pregnancy.
- Screening: routine universal TSH screening of asymptomatic pregnant women is not recommended in Canada — test targeted risk groups (prior thyroid disease/postpartum thyroiditis, known TPOAb+, goitre/symptoms, T1DM or other autoimmune disease, prior neck radiation, infertility/recurrent miscarriage).
- Iodine: start 150 µg/day iodine supplementation (standard prenatal vitamin) preconception through lactation (ATA 2026).
hyperthyroidism in pregnancy
gestational transient thyrotoxicosis (GTT) vs Graves disease
| feature | GTT (hCG-mediated) | Graves disease |
|---|---|---|
| context | hyperemesis gravidarum, multiple gestation, molar pregnancy | prior Graves, goitre, orbitopathy, pretibial myxoedema |
| TRAb / TSI | negative | positive |
| course | self-limited; resolves by 14–18 weeks | persists/flares; often eases in late pregnancy, flares postpartum |
| management | supportive (IV fluids, antiemetics) ± short-term propranolol; no ATDs | antithyroid drugs (PTU T1 → methimazole T2) |
Graves disease management (ATA 2026 & obstetric medicine)
- Diagnostic imaging: radioactive iodine uptake/scans and ¹³¹I therapy are strictly contraindicated in pregnancy and breastfeeding (→ prescribing in pregnancy and lactation).
- Stopping ATD at positive test: if euthyroid on a low stable dose (methimazole <5–10 mg/day or PTU <100–200 mg/day) for >6 months with low/negative TRAb, consider discontinuing ATD upon pregnancy confirmation and monitoring TSH/FT4 every 1–2 weeks in T1, then every 2–4 weeks in T2–T3 (ATA 2026).
- Active Graves requiring ATDs:
- First trimester (up to 16 weeks): propylthiouracil (PTU) preferred over methimazole (methimazole embryopathy: aplasia cutis, choanal/oesophageal atresia, omphalocele). Conversion ≈ 20 mg PTU = 1 mg methimazole (e.g. MMI 5 mg daily ≈ PTU 50 mg BID).
- Second trimester onward: switch to methimazole (lower maternal hepatotoxicity risk; ATA 2026 notes continuing PTU vs switching after 16 weeks lacks definitive RCT evidence, but Canadian practice switches to methimazole in T2).
- Dose goal: lowest effective ATD dose targeting free T4 at or slightly above the upper third of the reference range (overtreatment causes foetal hypothyroidism/goitre). Never use block-and-replace (except in isolated foetal hyperthyroidism when mother is hypothyroid post-RAI/surgery). Check TSH + FT4 every 2–4 weeks.
- β-blockers: short-term propranolol for severe palpitations/tremor; avoid prolonged use (risk of foetal growth restriction, bradycardia, neonatal hypoglycaemia — atenolol carries the strongest FGR signal).
- Surgery: reserved for exceptional refractory cases or severe ATD intolerance (ideally T2).
- TRAb / TSI and foetal monitoring: check TRAb/TSI at pregnancy confirmation (including women with prior RAI or thyroidectomy for Graves, as antibodies persist!). Repeat in T2 (18–22 weeks) — if >3× ULN (or on ATDs), initiate foetal ultrasound surveillance from 18–20 weeks (foetal HR, growth, goitre) and arrange paediatrics/neonatology evaluation at delivery for neonatal hyperthyroidism.
hypothyroidism in pregnancy
- Pre-existing hypothyroidism: increase levothyroxine by ~25–30% (2 extra tablets per week, i.e. 9 tablets/week) immediately upon positive pregnancy test (→ preconception counselling), check TSH every 4 weeks until mid-gestation and once around 30 weeks, and return to pre-pregnancy dose at delivery (recheck TSH at 6 weeks postpartum). Separate LT4 from prenatal iron/calcium by ≥4 hours.
- Overt hypothyroidism (high TSH + low FT4): treat immediately with levothyroxine (reduces miscarriage, preterm birth, preeclampsia, neurodevelopmental harm).
- Euthyroid TPOAb-positive: ATA 2026 strongly recommends against levothyroxine (and conditionally recommends against selenium, glucocorticoids, or IVIG) — instead monitor TSH every 4–6 weeks through mid-pregnancy.
- Subclinical hypothyroidism (SCH) — guideline shift to note:
- ATA 2026: strongly treats TSH >10 mU/L (profound SCH); for mild SCH (TSH above trimester ULN up to 10 mU/L), levothyroxine may be considered (conditional) only in the first trimester — for mild SCH diagnosed after the first trimester, ATA 2026 strongly recommends against levothyroxine.
- Classic ATA 2017 / exam framework: check TPOAb if TSH >2.5 mU/L → treat if TSH >4.0 (TPO+) or >10.0 (TPO−), consider if TSH 2.5–4.0 (TPO+) or 4.0–10.0 (TPO−), targeting TSH <2.5 mU/L.
postpartum thyroiditis (PPT)
Destructive autoimmune thyroiditis affecting ~5–10% of women within 12 months postpartum (especially TPOAb+ or T1DM).
- Classic triphasic course: thyrotoxic phase (1–4 months postpartum; low RAIU, negative TRAb — distinguishes from postpartum Graves relapse) → hypothyroid phase (4–8 months) → recovery by 12 months (~20–30% develop permanent hypothyroidism; high recurrence in future pregnancies).
- Management: never give ATDs for PPT thyrotoxicosis (use propranolol if symptomatic — safe in breastfeeding); treat symptomatic hypothyroid phase or TSH >10 with levothyroxine and trial weaning after 6–12 months (unless planning another pregnancy).
- Lactation & ATDs: methimazole (up to 20 mg/day) and PTU are compatible with breastfeeding (methimazole preferred; take after feeds).
Prepared 2026-11-19. Not yet verified — check every number against the sources.